Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal could complicate venture investors' exit, though Portola thinks not – as another would-be partner eyes second lead product.
You may also be interested in...
The Antidote To Competition: Portola’s Rivals Fund Study On Class-Wide Anticoagulant Antidote
Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.
Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding
Without a partner for its anticoagulant in an increasingly complex market, privately-held Portola takes $89 million in late-stage money to conduct Phase III trials on its own.
Back To The Drawing Board For Portola After Merck Returns Betrixaban
Merck & Co. returned the Phase III-ready oral Factor Xa inhibitor; Portola spins the news as an opportunity, but finding a new partner may be challenging.